来自官方财务报表的收入、利润与现金流历史。
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $1.7B | $1.4B | $1.0B | $829M | $660M | $443M | $268M | $196M | $152M | $317M | $147M | $135M | $75M | $55M | $42M | $56M | $14M | $14M | $9M | $4M | $1M |
| 毛利 | $1.3B | $1.1B | $856M | $637M | $521M | $362M | $224M | $150M | $142M | $285M | $113M | $106M | $53M | $49M | $41M | $56M | $13M | $13M | $8M | $4M | $1M |
| 毛利率% | 78.2% | 78.1% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% | 78.3% | 69.8% | 88.6% | 97.4% | 99.5% | 92.8% | 97.7% | 96.2% | 93.7% | 55.5% |
| 营业利润（EBIT） | $945M | $816M | $551M | $338M | $268M | $276M | $144M | ($68M) | ($69M) | $81M | ($83M) | ($27M) | ($63M) | ($80M) | ($54M) | ($20M) | ($54M) | ($58M) | ($50M) | ($28M) | ($16M) |
| 营业利润率% | 56.8% | 58.5% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.6% | 25.6% | -56.7% | -20.3% | -83.7% | -146.8% | -126.7% | -35.4% | -398.2% | -427.6% | -575.5% | -740.9% | -1587.3% |
| 净利 | $413M | $317M | $444M | $282M | $202M | $403M | $129M | ($72M) | ($80M) | $63M | ($103M) | ($32M) | ($68M) | ($83M) | ($54M) | ($20M) | ($53M) | ($58M) | ($49M) | ($24M) | ($15M) |
| 净利润率 % | 24.8% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% | -23.9% | -90.8% | -152.3% | -126.5% | -35.2% | -390.8% | -426.9% | -555.1% | -628.9% | -1502.6% |
| EBITDA | — | $573M | $657M | $452M | $316M | $279M | $148M | ($64M) | ($67M) | $83M | ($81M) | ($26M) | ($61M) | ($79M) | ($53M) | ($19M) | ($53M) | ($57M) | ($49M) | ($28M) | ($15M) |
| 每股收益（EPS） | $3.35 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 | $-0.67 | $-0.61 | $-0.32 | $-0.24 |
| 已发行股数 (M) | — | 124M | 129M | 134M | 141M | 147M | 141M | 144M | 144M | 139M | 128M | 127M | 123M | 113M | 111M | 103M | 94M | 87M | 80M | 74M | 63M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 HALO 交互式查看器。 /companies/us/HALO
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms